Literature DB >> 16933379

Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16933379

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  10 in total

Review 1.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

2.  Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Authors:  Otfried Kistner; M Keith Howard; Martin Spruth; Walter Wodal; Peter Brühl; Marijan Gerencer; Brian A Crowe; Helga Savidis-Dacho; Ian Livey; Manfred Reiter; Ines Mayerhofer; Christa Tauer; Leopold Grillberger; Wolfgang Mundt; Falko G Falkner; P Noel Barrett
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

3.  Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.

Authors:  Senthil Murugappan; Harshad P Patil; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs
Journal:  AAPS J       Date:  2014-01-31       Impact factor: 4.009

4.  Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

Authors:  Nadezhda E Yun; Nathaniel S Linde; Michele A Zacks; Ian G Barr; Aeron C Hurt; Jeanon N Smith; Natallia Dziuba; Michael R Holbrook; Lifang Zhang; John M Kilpatrick; C Shane Arnold; Slobodan Paessler
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

Review 5.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

6.  Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.

Authors:  Elena A Govorkova; Natalia A Ilyushina; David A Boltz; Alan Douglas; Neziha Yilmaz; Robert G Webster
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

7.  Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults.

Authors:  Benjamin Lasko; Dennis Reich; Anuradha Madan; François Roman; Ping Li; David Vaughn
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

8.  Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.

Authors:  Joanne M Langley; George Risi; Michael Caldwell; Larry Gilderman; Bruce Berwald; Charles Fogarty; Terry Poling; Dennis Riff; Mira Baron; Louise Frenette; Eric Sheldon; Harry Collins; Marc Shepard; Marc Dionne; Daniel Brune; Linda Ferguson; David Vaughn; Ping Li; Louis Fries
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

Review 9.  Vaccines for an influenza pandemic: scientific and political challenges.

Authors:  Lars R Haaheim
Journal:  Influenza Other Respir Viruses       Date:  2007-03       Impact factor: 4.380

10.  Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

Authors:  Katja Höschler; Robin Gopal; Nick Andrews; Melanie Saville; Stephanie Pepin; John Wood; Maria C Zambon
Journal:  Influenza Other Respir Viruses       Date:  2007 Sep-Nov       Impact factor: 4.380
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.